STOCK TITAN

Cogent Biosciences (NASDAQ: COGT) 2026 meeting backs board, auditor and pay

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Cogent Biosciences, Inc. held its 2026 Annual Meeting of Stockholders on June 9, 2026. As of the April 13, 2026 record date, 170,801,004 shares of common stock were entitled to vote.

All three director nominees, Chris Cain, Ph.D., Arlene Morris, and Todd Shegog, were elected. Stockholders ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm and approved the advisory vote on executive compensation.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Shares entitled to vote 170,801,004 shares Common stock as of April 13, 2026 record date
Votes for Chris Cain, Ph.D. 124,356,809 votes Proposal 1 director election
Votes for Arlene Morris 120,180,517 votes Proposal 1 director election
Votes for Todd Shegog 124,143,441 votes Proposal 1 director election
Votes for auditor ratification 154,001,553 votes Proposal 2 PricewaterhouseCoopers LLP ratification
Votes for say-on-pay 129,183,846 votes Proposal 3 advisory vote on executive compensation
Annual Meeting of Stockholders financial
"held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”)"
record date financial
"As of the close of business on April 13, 2026, the record date"
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.
broker non-votes financial
"Votes For | | | Votes Withheld | | | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"Ratification of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Advisory Vote on Executive Compensation financial
"Proposal 3. Advisory Vote on Executive Compensation"
A non-binding shareholder vote allowing investors to approve or reject the pay packages and compensation policies for a company’s top executives. It matters because the outcome tells the board whether owners are satisfied with executive pay and can prompt changes in policy or leadership much like a customer survey prompts a company to adjust its product — signaled approval can support management credibility, while rejection may increase scrutiny and affect investor confidence.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001622229 0001622229 2026-06-09 2026-06-09
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): June 9, 2026

 

 

COGENT BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38443   46-5308248

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

180 Third Avenue, 4th Floor

Waltham, Massachusetts

  02451
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 945-5576

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common stock, $0.001 Par Value   COGT   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


On Tuesday, June 9, 2026, Cogent Biosciences, Inc., a Delaware corporation (the “Company”), held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) at 9:00 a.m., Eastern Time. As of the close of business on April 13, 2026, the record date for the Annual Meeting, there were 170,801,004 shares of common stock, par value 0.001 per share (the “Common Stock”), entitled to vote at the meeting.

Item 5.07. Submission of Matters to a Vote of Security Holders.

At the Annual Meeting, each of the Company’s director nominees was elected and each of the other proposals voted on were approved. The final voting results are set forth below.

 

     Votes
For
     Votes
Withheld
     Broker
Non-Votes
 

Proposal 1. Election of Directors

        

Chris Cain, Ph.D.

     124,356,809        18,837,092        11,240,612  

Arlene Morris

     120,180,517        23,013,384        11,240,612  

Todd Shegog

     124,143,441        19,050,460        11,240,612  

 

     Votes
For
     Votes
Against
     Abstentions      Broker Non-Votes  
Proposal 2. Ratification of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm      154,001,553        399,367        33,593        0  

 

     Votes
For
     Votes
Against
     Abstentions      Broker Non-Votes  
Proposal 3. Advisory Vote on Executive Compensation      129,183,846        13,977,449        32,606        11,240,612  


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 11, 2026   COGENT BIOSCIENCES, INC.
    By:  

/s/ Evan Kearns

      Evan Kearns
      Chief Legal Officer and Corporate Secretary

FAQ

What did Cogent Biosciences (COGT) stockholders vote on at the 2026 Annual Meeting?

Stockholders voted on electing three directors, ratifying PricewaterhouseCoopers LLP as independent registered public accounting firm, and approving an advisory vote on executive compensation. All three proposals received sufficient support to pass at the 2026 Annual Meeting.

Were Cogent Biosciences (COGT) director nominees elected at the 2026 Annual Meeting?

Yes, all three director nominees were elected. Chris Cain, Ph.D., received 124,356,809 votes for, Arlene Morris received 120,180,517 votes for, and Todd Shegog received 124,143,441 votes for, each with additional withheld and broker non-vote totals reported.

How did Cogent Biosciences (COGT) stockholders vote on the auditor ratification?

Stockholders strongly supported ratifying PricewaterhouseCoopers LLP as independent registered public accounting firm, with 154,001,553 votes for, 399,367 votes against, and 33,593 abstentions. There were no broker non-votes reported for this ratification proposal at the 2026 Annual Meeting.

What was the outcome of Cogent Biosciences’ (COGT) say-on-pay vote in 2026?

Stockholders approved the advisory vote on executive compensation. The proposal received 129,183,846 votes for, 13,977,449 votes against, 32,606 abstentions, and 11,240,612 broker non-votes, indicating overall support for the company’s executive pay program that year.

How many Cogent Biosciences (COGT) shares were entitled to vote at the 2026 Annual Meeting?

A total of 170,801,004 shares of Cogent Biosciences common stock were entitled to vote as of the April 13, 2026 record date. These shares formed the voting base for director elections, auditor ratification, and the advisory vote on executive compensation.

When and where did Cogent Biosciences (COGT) hold its 2026 Annual Meeting of Stockholders?

The company held its 2026 Annual Meeting of Stockholders on June 9, 2026, at 9:00 a.m. Eastern Time. Cogent Biosciences’ principal executive offices are located at 180 Third Avenue, 4th Floor, Waltham, Massachusetts 02451, which anchors its corporate base.

Filing Exhibits & Attachments

3 documents